FMP
Impel Pharmaceuticals Inc.
IMPL
NASDAQ
Inactive Equity
Impel Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. The company is also developing INP105, an upper nasal formulation of olanzapine for the acute treatment of agitation and aggression in autism spectrum disorder; and INP107, an upper nasal formulation of carbidopa/levodopa, which has completed Phase IIa clinical trial for the treatment of OFF episodes in Parkinson's disease. Impel Pharmaceuticals Inc. was formerly known as Impel NeuroPharma, Inc. and changed its name to Impel Pharmaceuticals Inc. in April 2022. Impel Pharmaceuticals Inc. was incorporated in 2008 and is headquartered in Seattle, Washington.
0.04 USD
-0.015 (-37.5%)
About
ceo
Mr. Leonard S. Paolillo
sector
Healthcare
industry
Biotechnology
website
https://impelpharma.com
exchange
NASDAQ
Description
Impel Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. The company is also developing INP105, an upper nasal formulation of olanzapine for the acute treatment of agitation and aggression in autism spectrum disorder; and INP107, an upper nasal formulation of carbidopa/levodopa, which has completed Phase IIa clinical trial for the treatment of OFF episodes in Parkinson's disease. Impel Pharmaceuticals Inc. was f...
CIK
0001445499
ISIN
US45258K1097
CUSIP
45258K109
Address
201 Elliott Avenue West
Phone
206 568 1466
Country
US
Employee
160
IPO Date
Apr 23, 2021
Summary
CIK
0001445499
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
45258K109
ISIN
US45258K1097
Country
US
Price
0.04
Beta
1.17
Volume Avg.
1.02M
Market Cap
956k
Shares
-
52-Week
0.0212-4.2
DCF
0
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-0.01
P/B
-
Website
https://impelpharma.com
Historical Prices
We are unable to load the chart at this time.
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
Upgrades and Downgrades
We are unable to load this data!
People Also Watch
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest IMPL News
It looks like there's no news available.
